Cone Health Women's Hospital

All BayCare Acute-Care Hospitals Earn Top Score for Patient Safety

Retrieved on: 
Lundi, novembre 6, 2023
Quality, National Association Medical Staff Services, Safety, Cone Health Women's Hospital, Patient safety organization, BayCare Ballpark, Children's Hospital, Hospital, Child, Patient, Nursing

BayCare Alliant Hospital, St. Joseph's Children's Hospital, St. Joseph's Women's Hospital and Winter Haven Women's Hospital are not given safety grades because the Leapfrog Group focuses on general, acute-care hospitals.

Key Points: 
  • BayCare Alliant Hospital, St. Joseph's Children's Hospital, St. Joseph's Women's Hospital and Winter Haven Women's Hospital are not given safety grades because the Leapfrog Group focuses on general, acute-care hospitals.
  • Additionally, BayCare Hospital Wesley Chapel does not have a grade because it opened in March 2023, so there is not enough data for it to have a grade yet.
  • "This achievement underscores that Quality serves as BayCare's true north and demonstrates our deep, unwavering commitment to patient safety.
  • The Leapfrog Hospital Safety Grade is a composite score that is comprised of the following:

Chaffin Luhana Foundation Announces Winner of 2023 Anti-Distracted Driving Scholarship

Retrieved on: 
Vendredi, novembre 3, 2023
Essay, Drinking, Mobile, Attention, Fatality, Student, AAA, NHTSA, National Highway Traffic Safety Administration, Liberty Mutual, Eating, Injury, Risk, Oakland Catholic High School, Accident, Safety, Cone Health Women's Hospital, SADD, Hospital, Perception, Ontario Students Against Impaired Driving, Parent, Mobile phone, Road, Ridesharing, Brigham

PITTSBURGH, Nov. 3, 2023 /PRNewswire-PRWeb/ -- The Chaffin Luhana Foundation is pleased to announce Tia Kaschauer as the winner of the 2023 Chaffin Luhana Anti-Distracted Driving Scholarship.

Key Points: 
  • Tia Kaschauer, a student at Oakland Catholic High School in Pittsburgh, Pennsylvania, has been awarded the 2023 Chaffin Luhana Anti-Distracted Driving Scholarship.
  • Established by law partners Eric Chaffin and Roopal Luhana in 2010, the Chaffin Luhana Foundation has long sought to encourage an end to distracted driving accidents in the U.S.
  • The Anti-Distracted Driving Scholarship—a $2,500 award that the Foundation provides annually—is part of these efforts, and rewards one deserving student based on their essay raising awareness for the dangers of distracted driving.
  • "You can't read Ms. Kaschauer's essay without being moved by the experiences she has gone through," said Roopal Luhana, Founding Partner at Chaffin Luhana.

The Department of Health - Abu Dhabi inaugurates a nationwide Clinical Genomic Medicine and Genetic Counselling programme for 100 Emirati Physicians

Retrieved on: 
Mercredi, novembre 1, 2023
Knowledge, Mass General Brigham, EGP, Genomics, Harvard Medical School, Genetic, DSM-IV codes, Physician, Science, technology, engineering, and mathematics, International Grape Genome Program, Genetics, ABU, Department of Health (Abu Dhabi), Research, Artificial intelligence, Quality of life, Khalifa University, Trustee, International Center, Medicine, Hospital, Partnership, Emirate, Public, Mass, Cone Health Women's Hospital, Cancer, Diagnosis, Clinical Genome Resource, Doh, DNA, Nursing, Management, Science, Emirati, Brigham

ABU DHABI, UAE, Nov. 1, 2023 /PRNewswire/ -- In line with its continuous efforts to upskill the national healthcare workforce, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has launched the Clinical Genomic Medicine and Genetic Counselling Programme for 100 Emirati physicians from different healthcare facilities across the UAE. The programme is offered by DoH, in partnership with the International Center for Genetic Disease (iCGD), Brigham and Women's Hospital, Harvard Medical School, and Khalifa University of Science and Technology, which hosted the inaugural ceremony. The programme is considered to be iCGD's largest and most comprehensive national genomics educational programmes, reflecting DoH's commitment to upskilling physicians in genomic medicine and equipping them with the necessary knowledge and skills.

Key Points: 
  • Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi, Professor Sir John O'Reilly, President of Khalifa University, H.E.
  • Furthermore, it will enable participants to become proficient in diagnostics, clinical decision-making, and the analysis and interpretation of genomic data.
  • Through this, the programme will contribute to building the professional and genomic medicine capacity essential for the successful implementation of the Emirati Genome Programme.
  • Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi said: "Abu Dhabi has positioned itself as the region's leading destination for healthcare and innovation in life sciences.

The Department of Health - Abu Dhabi inaugurates a nationwide Clinical Genomic Medicine and Genetic Counselling programme for 100 Emirati Physicians

Retrieved on: 
Mercredi, novembre 1, 2023
Knowledge, Mass General Brigham, EGP, Genomics, Harvard Medical School, Genetic, DSM-IV codes, Physician, Science, technology, engineering, and mathematics, International Grape Genome Program, Genetics, ABU, Department of Health (Abu Dhabi), Research, Artificial intelligence, Quality of life, Khalifa University, Trustee, International Center, Medicine, Hospital, Partnership, Emirate, Public, Mass, Cone Health Women's Hospital, Cancer, Diagnosis, Clinical Genome Resource, Doh, DNA, Nursing, Management, Science, Emirati, Brigham

ABU DHABI, UAE, Nov. 1, 2023 /PRNewswire/ -- In line with its continuous efforts to upskill the national healthcare workforce, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has launched the Clinical Genomic Medicine and Genetic Counselling Programme for 100 Emirati physicians from different healthcare facilities across the UAE. The programme is offered by DoH, in partnership with the International Center for Genetic Disease (iCGD), Brigham and Women's Hospital, Harvard Medical School, and Khalifa University of Science and Technology, which hosted the inaugural ceremony. The programme is considered to be iCGD's largest and most comprehensive national genomics educational programmes, reflecting DoH's commitment to upskilling physicians in genomic medicine and equipping them with the necessary knowledge and skills.

Key Points: 
  • Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi, Professor Sir John O'Reilly, President of Khalifa University, H.E.
  • Furthermore, it will enable participants to become proficient in diagnostics, clinical decision-making, and the analysis and interpretation of genomic data.
  • Through this, the programme will contribute to building the professional and genomic medicine capacity essential for the successful implementation of the Emirati Genome Programme.
  • Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi said: "Abu Dhabi has positioned itself as the region's leading destination for healthcare and innovation in life sciences.

The Department of Health - Abu Dhabi launches first of its kind, nationwide Clinical Genomic Medicine and Genetic Counselling Programme

Retrieved on: 
Mercredi, novembre 1, 2023
Knowledge, Mass General Brigham, EGP, Harvard Medical School, DSM-IV codes, Genetic, Genetics, United Arab Emirates, ABU, Department of Health (Abu Dhabi), Artificial intelligence, Quality of life, International Center, Genomics, Khalifa University, Medicine, Partnership, Emirate, Mass, Cone Health Women's Hospital, Cancer, Hospital, Diagnosis, The Department, Doh, Pharmaceutical industry, Management

ABU DHABI, UAE, Nov. 1, 2023 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, announced the launch of a Clinical Genomic Medicine and Genetic Counselling Programme for 100 Emirati physicians, from multiple healthcare facilities across the UAE.

Key Points: 
  • ABU DHABI, UAE, Nov. 1, 2023 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, announced the launch of a Clinical Genomic Medicine and Genetic Counselling Programme for 100 Emirati physicians, from multiple healthcare facilities across the UAE.
  • This announcement is the first outcome of DoH's partnership with iCGD, following the Declaration of Collaboration signed in June 2023.
  • The unique six-month programme, delivered by experts in the field, aims to equip doctors with the necessary knowledge and skills to handle genetic and genomic issues in a clinical setting.
  • Over 400,000 genetic samples have been collected as part of the programme, marking substantial progress towards the national target of 1 million.

The Department of Health - Abu Dhabi launches first of its kind, nationwide Clinical Genomic Medicine and Genetic Counselling Programme

Retrieved on: 
Mercredi, novembre 1, 2023
Knowledge, Mass General Brigham, EGP, Harvard Medical School, DSM-IV codes, Genetic, Genetics, United Arab Emirates, ABU, Department of Health (Abu Dhabi), Artificial intelligence, Quality of life, International Center, Genomics, Khalifa University, Medicine, Partnership, Emirate, Mass, Cone Health Women's Hospital, Cancer, Hospital, Diagnosis, The Department, Doh, Pharmaceutical industry, Management

ABU DHABI, UAE , Nov. 1, 2023 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, announced the launch of a Clinical Genomic Medicine and Genetic Counselling Programme for 100 Emirati physicians, from multiple healthcare facilities across the UAE.

Key Points: 
  • ABU DHABI, UAE , Nov. 1, 2023 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, announced the launch of a Clinical Genomic Medicine and Genetic Counselling Programme for 100 Emirati physicians, from multiple healthcare facilities across the UAE.
  • This announcement is the first outcome of DoH's partnership with iCGD, following the Declaration of Collaboration signed in June 2023.
  • The unique six-month programme, delivered by experts in the field, aims to equip doctors with the necessary knowledge and skills to handle genetic and genomic issues in a clinical setting.
  • Over 400,000 genetic samples have been collected as part of the programme, marking substantial progress towards the national target of 1 million.

Virology Education Presents the Demystifying Long COVID-19 International Conference 2023 7-9 December 2023

Retrieved on: 
Jeudi, octobre 19, 2023
Health, Infectious Diseases, COVID-19, General Health, Research, Science, WHO, Harvard Medical School, COVID, University of Paris, SARS-CoV-2, Face, University of California, Sheba Medical Center, Inflammation, Light, Westminster Hospital, Disease, Caregiver, Risk, University, Public, Cone Health Women's Hospital, Patient, Hospital, Pharmaceutical industry, Medical device, Vaccine, Nursing

Long COVID - a multisystem condition that significantly burdens individuals and public health, experienced by approximately 10-20 % of people infected by SARS-CoV-2.

Key Points: 
  • Long COVID - a multisystem condition that significantly burdens individuals and public health, experienced by approximately 10-20 % of people infected by SARS-CoV-2.
  • This new initiative provides a global platform for this vital cross-disciplinary discussion.
  • What do we know about the global prevalence, risk factors, and long-term evolution of long COVID?
  • How to improve the care pathways in the light of what is organized in different countries?

New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement

Retrieved on: 
Lundi, octobre 23, 2023
Week, DSM-IV codes, American College, Janssen, Crohn's disease, UC, ACG, American College of Gastroenterology, Ulcerative colitis, HOUSE, Janssen Pharmaceuticals, Cone Health Women's Hospital, Patient, Hospital, Pharmaceutical industry, Birth control

SPRING HOUSE, Pa., Oct. 23, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, today announced new data from the QUASAR Phase 3 Induction Study demonstrating the efficacy and safety profile of TREMFYA® (guselkumab), a selective IL-23 p19 inhibitor, in patients with moderately to severely active ulcerative colitis (UC) through 24 weeks.1 High rates of clinical responsea were observed at Weeks 12 or 24, with no new safety signals observed compared to the safety profile of TREMFYA in its approved indications.1 Symptomatic responseb and improvements in patient-reported outcomes of rectal bleeding and absolute stool number were observed as early as one week after a single intravenous (IV) induction dose, with symptomatic response evident in more than two-thirds of patients at Week 12.2 These data are among Janssen's 20 oral and poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Vancouver, Canada, October 20-25, 2023.

Key Points: 
  • Additional data show symptomatic response as early as one week after the first induction dose, with symptomatic improvements increasing through Week 12
    SPRING HOUSE, Pa., Oct. 23, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, today announced new data from the QUASAR Phase 3 Induction Study demonstrating the efficacy and safety profile of TREMFYA® (guselkumab), a selective IL-23 p19 inhibitor, in patients with moderately to severely active ulcerative colitis (UC) through 24 weeks.1 High rates of clinical responsea were observed at Weeks 12 or 24, with no new safety signals observed compared to the safety profile of TREMFYA in its approved indications.1 Symptomatic responseb and improvements in patient-reported outcomes of rectal bleeding and absolute stool number were observed as early as one week after a single intravenous (IV) induction dose, with symptomatic response evident in more than two-thirds of patients at Week 12.2 These data are among Janssen's 20 oral and poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Vancouver, Canada, October 20-25, 2023.
  • "Ulcerative colitis is a complex immune-mediated disease that can cause a wide range of often-debilitating symptoms," said study author Jessica R. Allegretti, M.D., Medical Director, Crohn's and Colitis Center at the Brigham and Women's Hospital, Boston, MA, USA.c "Results from the QUASAR studies support the potential of TREMFYA as a durable and fast-acting treatment option."
  • QUASAR Cumulative Clinical Response Results Through Week 24:
    Among TREMFYA-treated patients who were not in clinical response to IV induction therapy at Week 12 and who then received subcutaneous treatment for an additional 12 weeks, 55 percent (66/120) achieved clinical response at Week 24.1
    QUASAR Cumulative Safety Results Through Week 24:
    Safety findings through the final safety visit were consistent with Week 12 results; no new safety signals were identified.1
    QUASAR Early Symptomatic Response Data: Week 1 Through Week 12:
    As early as Week 1 and increasing through Week 12, greater symptomatic improvements were seen in patients treated with TREMFYA compared with placebo with treatment differences for TREMFYA versus placebo evident across outcomes.2

USA Health Children's & Women's Hospital Goes Live with AdaptX for Maternal Health Equity Initiative

Retrieved on: 
Jeudi, octobre 19, 2023
Science, Health care, Health, Bachelor of Medicine, Bachelor of Surgery, Hope, Mortality, RN, Disease, Health equity, Partnership, Obstetrics, Mother, Cone Health Women's Hospital, Investment, Patient, Hospital, MSN, Canadian Foundation for Healthcare Improvement, IHI, Nursing, MD, Merck

SEATTLE, Oct. 19, 2023 /PRNewswire-PRWeb/ -- AdaptX®, a self-serve clinical management solution company, today announced the go-live of Alabama-based USA Health Children's and Women's Hospital with AdaptX's Obstetrics Advisor™ solution to improve maternal health equity, in partnership with the Institute of Healthcare Improvement (IHI) and with generous support from Merck for Mothers.

Key Points: 
  • "AdaptX is transforming the way we approach maternal health equity," said Vicki Curtis, MSN, RN, RNC-OB, director of women's services for USA Health Children's and Women's Hospital.
  • As part of this innovative maternal health initiative, USA Health Children's & Women's Hospital is receiving unique change management training and support from the IHI's quality improvement experts, reflecting the IHI's commitment to improving health equity.
  • I'm hopeful that this partnership and approach will show practical solutions that will close maternal health equity gaps."
  • "The AdaptX team is honored to partner with USA Health and the IHI to improve maternal health equity," said Warren Ratliff, chief executive officer of AdaptX.

Alopexx Announces Presentation at IDWeek 2023

Retrieved on: 
Mercredi, octobre 11, 2023
Deficit spending, Microbial pathogenesis, Alzheimer's disease, Hospital, Cone Health Women's Hospital, Vaccination, Dementia, Brigham and Women's Hospital, Disease, Mouse, Assistant, AD, Human, Parasitism, Research, Pharmaceutical industry, MD, Medicine

CAMBRIDGE, Mass., Oct. 11, 2023 /PRNewswire/ -- Alopexx, Inc., a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal and parasitic infections, today announced that Colette Cywes-Bentley, Ph.D., Assistant Professor of Medicine at Brigham and Women's Hospital, is scheduled to present pre-clinical data at IDWeek 2023's Microbial Pathogenesis of Alzheimer's Disease symposium being held October 11-15, 2023 in Boston, MA.

Key Points: 
  • Dr. Colette Cywes-Bentley will present pre-clinical data on the molecular mechanisms of microbiota-driven neuroinflammation and the therapeutic potential of targeting PNAG in the treatment and prevention of Alzheimer's Disease.
  • The presentation will discuss the results evaluating the role of targeting PNAG utilizing Alopexx's vaccine, AV0328 and monoclonal antibody F598.
  • Her research has shown that microbial fragments containing PNAG are present in the brains of mice and humans with Alzheimer's disease.
  • In murine models of Alzheimer's Disease, vaccination with Alopexx's AV0328 vaccine is able to prevent cognitive decline.